Evidence map›Paper›PMID 36394017›Full record

ArticleFrontiers in bioengineering and biotechnology2022

Improving the

Chenli Qiu, Jing Wang, Lingyan Zhu, Xiaobo Cheng, Bili Xia, Yanling Jin, Ran Qin, LinXia Zhang, Huiliang Hu, Jia Yan and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Chenli QiuShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Jing WangShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Lingyan ZhuShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Xiaobo ChengShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Bili XiaShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Yanling JinShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Ran QinShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
LinXia ZhangShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Huiliang HuShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Jia YanShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Chen ZhaoShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Xiaoyan ZhangShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Jianqing XuShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Shanghai Public Health Clinical Center · CNObstetrics and Gynecology Hospital of Fudan University · CNZhongshan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toll-like receptors (TLRs) are important pattern recognition receptor(s) known to mediate the sensing of invading pathogens and subsequent immune responses. In this study, we investigate whether TLRs could be explored for the preparation of human CD8

Indexed as

adoptive cell therapyagonistscell proliferationhuman PD1+ CD8+ T cellstoll-like receptorstumor cell killing

Identifiers

PMID36394017
PMCPMC9659750
OpenAlexW4307679270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.